"Takeda and AC Immune SA today announced an exclusive, worldwide option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24.060 for the treatment of Alzheimer’s disease," the company said in a statement on Monday.
The statement added that AC Immune will receive an upfront payment of $100 million "and be eligible to receive an option exercise fee and additional potential development, commercial and sales-based milestones of up to approximately $2.1 billion if all related milestones are achieved over the course of the agreement."
In addition, the Swiss company will be able to receive "tiered double-digit royalties on worldwide net sales," the statement read.